Summary

The current evidence to guide adjuvant endocrine therapy in women with ER-positive breast cancer, including tamoxifen, aromatase inhibitors, and ovarian function suppression is reviewed. The studies include ATLAS, aTTom, SOFT, ECOG E3193, TEXT, ABCSG 12, and the Early Breast Cancer Trialists’ Collaborative Group meta-analysis.